Chiesi

Pharma

After Amryt buy, Chiesi names Baxter vet Accogli its new CEO

A few weeks after acquiring rare disease specialist Amryt for $1.48 billion, Italy’s Chiesi Farmaceutici has named a new CEO, Giuseppe Accogli.
Kevin Dunleavy Jan 30, 2023 2:00am

Chiesi supports painted hospitals project

Jun 3, 2022 9:00am

Chiesi study highlights economic burden of rare diseases

Mar 14, 2022 11:33am

Glaxo wins much-needed FDA nod for blockbuster prospect Trelegy

Sep 19, 2017 9:33am

Can other gene therapy developers avoid Glybera's fate?

May 4, 2016 10:55am